La Jolla Pharmaceutical Co (LJPC)

28.62
0.44 1.60
NASDAQ : Health Care
Prev Close 28.18
Open 27.72
Day Low/High 27.72 / 29.68
52 Wk Low/High 12.68 / 44.99
Volume 238.87K
Avg Volume 885.80K
Exchange NASDAQ
Shares Outstanding 18.26M
Market Cap 514.98M
EPS -4.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest Makes 103.8% Move For LJPC

Short Interest Makes 103.8% Move For LJPC

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,829,419 share increase in total short interest for La Jolla Pharmaceutical Co. , to 3,591,287, an increase of 103.83% since 02/28/2017.

La Jolla Pharmaceutical Company Announces Pricing Of Public Offering Of Common Stock

La Jolla Pharmaceutical Company Announces Pricing Of Public Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("La Jolla" or the "Company"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering Of Common Stock

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("La Jolla" or the "Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Insider Bets Paying Off At LJPC As New 52-Week High Reached

Insider Bets Paying Off At LJPC As New 52-Week High Reached

In trading on Monday, shares of La Jolla Pharmaceutical Co. touched a new 52-week high of $39.28/share.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

6 Stocks with Unusual Volume Activity

6 Stocks with Unusual Volume Activity

When stocks move with unusual volume, it can signal insider buying and selling.

6 Stocks on the Move With Unusual Volume

6 Stocks on the Move With Unusual Volume

Here's a technical look at how to trade a number of stocks rising with unusual volume flow.

Stocks Inch Higher in Cautious Trading Ahead of Trump's Budget, Tax Plans

Stocks Inch Higher in Cautious Trading Ahead of Trump's Budget, Tax Plans

Stocks inch higher as investors await more detail on changes to the federal budget and the tax code.

How to Trade 7 Most-Active Stocks: AMD, La Jolla Pharma, Tesla and More

How to Trade 7 Most-Active Stocks: AMD, La Jolla Pharma, Tesla and More

Here's how to trade seven of the most active names on the market.

Stocks Trade Flat as Trump Pledges $54B Bump in Defense Spending

Stocks Trade Flat as Trump Pledges $54B Bump in Defense Spending

Stocks trade flat on Monday as Donald Trump offers some detail about his incoming budget.

What You Need to Know About La Jolla's Shock-Treatment Drug

What You Need to Know About La Jolla's Shock-Treatment Drug

LJPC-501 is a proprietary formulation of a protein that helps to regulate blood pressure.

Stock Futures Retreat as Wall Street Awaits Details of Trump's Tax Plan

Stock Futures Retreat as Wall Street Awaits Details of Trump's Tax Plan

Stock futures, including the Dow Jones Industrial Average, move away from recent records as Wall Street awaits tax and spending details from the White House.

La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients

La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients

The company intends to submit a marketing application for LJPC-501 to the FDA in the second half of the year, pending the outcome of a meeting with regulators.

La Jolla Pharmaceutical Stock Spikes on Positive Trial Results

La Jolla Pharmaceutical Stock Spikes on Positive Trial Results

La Jolla (LJPC) is extending tests after phase 3 hypotension treatment trials showed positive results.

La Jolla Pharmaceutical Company Announces Positive Top-Line Results From ATHOS-3 Phase 3 Study Of LJPC-501

La Jolla Pharmaceutical Company Announces Positive Top-Line Results From ATHOS-3 Phase 3 Study Of LJPC-501

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla), today announced positive top-line results from the ATHOS-3 ( Angiotensin II for the Treatment of High- Output Shock) Phase 3 study of LJPC-501 (angiotensin...

La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2016 Financial Results And Corporate Progress

La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2016 Financial Results And Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Notable Monday Option Activity: LJPC, ILG, PF

Notable Monday Option Activity: LJPC, ILG, PF

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in La Jolla Pharmaceutical Co. , where a total of 5,394 contracts have traded so far, representing approximately 539,400 underlying shares.

Notable Friday Option Activity: LJPC, AIG, AVXL

Notable Friday Option Activity: LJPC, AIG, AVXL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in La Jolla Pharmaceutical Co. , where a total volume of 823 contracts has been traded thus far today, a contract volume which is representative of approximately 82,300 underlying shares (given that every 1 contract represents 100 underlying shares).

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2016 And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2016 And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,...

La Jolla Pharmaceutical Company Receives Positive Opinion From European Orphan Committee For LJPC-401

La Jolla Pharmaceutical Company Receives Positive Opinion From European Orphan Committee For LJPC-401

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Short Interest Expands By 32% For LJPC

Short Interest Expands By 32% For LJPC

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 467,643 share increase in total short interest for La Jolla Pharmaceutical Co. , to 1,933,572, an increase of 31.90% since 09/15/2016.

Commit To Buy La Jolla Pharmaceutical Co. At $15, Earn 24.5% Annualized Using Options

Commit To Buy La Jolla Pharmaceutical Co. At $15, Earn 24.5% Annualized Using Options

Investors eyeing a purchase of La Jolla Pharmaceutical Co. shares, but cautious about paying the going market price of $23.30/share, might benefit from considering selling puts among the alternative strategies at their disposal.

These 7 Stocks Are Spiking on Big Volume

These 7 Stocks Are Spiking on Big Volume

Here's a technical look at how to trade several stocks rising on unusual volume.

Shark Bites: Aratana Therapeutics Makes Its Move

Shark Bites: Aratana Therapeutics Makes Its Move

Typically a move like this will bring in momentum buyers that chase breakouts.

La Jolla Pharmaceutical Company Announces Agreement With European Medicines Agency On Pivotal Study Of LJPC-401

La Jolla Pharmaceutical Company Announces Agreement With European Medicines Agency On Pivotal Study Of LJPC-401

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,...

La Jolla Pharmaceutical Company Reports Positive Results From Phase 1 Study Of LJPC-401

La Jolla Pharmaceutical Company Reports Positive Results From Phase 1 Study Of LJPC-401

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,...

LJPC: Insiders vs. Shorts

LJPC: Insiders vs. Shorts

The most recent short interest data was recently released for the 07/29/2016 settlement date, and La Jolla Pharmaceutical Co. is one of the most shorted stocks of the Russell 3000, based on 17.92 "days to cover" versus the median component at 6.42.

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2016

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2016

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,...